Clinical Trials · NCT07455903
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Baptist Health South Florida
- Enrollment
- 50
- Start date
- Apr 2026
- Locations
- 1 site, United States
- Primary endpoint
- Objective response rate (ORR) based on PSMA PET